Navigation Links
Current and Emerging Therapies Have No Advantage Over Enbrel in Reducing the Signs and Symptoms of Rheumatoid Arthritis
Date:1/28/2009

Golimumab Will Earn Decision Resources' Gold Standard for Rheumatoid Arthritis in 2012, According to a New Report from Decision Resources

WALTHAM, Mass., Jan. 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed rheumatologists say that a therapy's effect on reducing the signs and symptoms of rheumatoid arthritis at one year is the attribute that most influences their prescribing decisions in treating the disease. Clinical data and the opinions of interviewed thought leaders indicate that current and emerging therapies have no advantage in this attribute over Amgen/Wyeth/Takeda's Enbrel (etanercept), the market sales-leading agent.

The new report entitled Rheumatoid Arthritis: A Novel Oral Therapy Must Satisfy Physicians' High Expectations for Efficacy to Tap Significant Market Opportunity finds that an oral disease-modifying drug with a novel mechanism of action that is priced 20 percent lower than etanercept plus methotrexate would earn a 25 percent patient share in the United States and a 20 percent patient share in Europe, according to surveyed U.S. and European rheumatologists.

Decision Resources' proprietary clinical gold standard in 2008 for rheumatoid arthritis was Enbrel, most notably because of its superior efficacy in inhibiting/slowing structural damage progression at one and two years compared with other agents in the market. Following its approval for the indication, which is likely to occur in 2010, Centocor/Schering-Plough/Mitsubishi Tanabe/Janssen's Simponi (golimumab) will earn Decision Resources' gold standard for rheumatoid arthritis in 2012. Although Simponi's overall efficacy, safety and tolerability do not match that of Enbrel, its advantages in delivery differentiate it from Enbrel.

"Simponi ranks higher than Enbrel on the measures of dosage formulation and d
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
2. Glass Lewis Recommends Arrow Shareholders Vote on the White Proxy Card for Merger With Teleflex and for Current Board of Directors at Arrow Annual Meeting
3. Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Directors
4. Morris Animal Foundation 2008 Sponsorship Guide Available, Details Current Animal Health Studies
5. Experimental drug boosts survival in recurrent ovarian cancer
6. Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees
7. Stop eating for two: obese moms-to-be should gain less weight than currently recommended
8. Switching to MA Coverage Unlikely for Current Beneficiaries With MediGap or Medicare Only
9. The Current Recall of Boy Scouts of Americas Plastic Badges Does Not Affect Embroidered Insignia, Badges & Awards Produced by Lion Brothers Company Inc.
10. Purified Fish Oil Concentrates Offer Solution to Current Seafood Controversy for Pregnant and Breastfeeding Women!
11. ALEVE-D(R) Sinus & Cold Offers Option for the More Than 50% of Consumers Not Satisfied with Current Sinus Medication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 Julie Kuriakose, MD; ... , will discuss how restaurants can become more allergy-friendly ... dietary restrictions at the 2014 Allergy Eats Food ... October 21 in New York City. , “I’m extremely ... to such an engaged industry audience. As food allergies ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 In ... well as better data capture and management functions ... ClinCapture electronic data capture (EDC) system. ClinCapture offers ... ability to easily manage clinical trial data and ... cement Synergy’s position as the leading clinical research ...
(Date:9/30/2014)... From October 12-15, MMS, Inc. (Medical ... SHSMD Connections Annual Conference in San Diego, California. ... Development (SHSMD) is proud to host the event of ... and strategic planning professionals in San Diego this fall: ... conference is a four-day event designed to equip ...
(Date:9/30/2014)... Bibliomotion is proud to announce the release of ... Social Age by Frank Guglielmo and Sudhanshu ... authors apply their leadership coaching experience to introduce Social Leadership ... and behaviors that leaders must adopt in order to thrive ... read a review of The Social Leader in Dialogue Reviews. ...
(Date:9/30/2014)... JACKSON, Tenn. (PRWEB) September 30, 2014 ... Oct. 4, from 10 a.m. to 2 p.m. at ... Pinson). Woodmen of the World sponsors this family-oriented festival, ... free, and the festival will feature a car show, ... climbing wall, hayride and children’s games. Also, Lightning McQueen ...
Breaking Medicine News(10 mins):Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 2Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 3Health News:Synergy Research Group Opts for Clinovo 2Health News:Synergy Research Group Opts for Clinovo 3Health News:MMS, Inc. (Medical Marketing Service) to Attend the 2014 SHSMD Connections Annual Conference in October 2Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 2Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 3Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 4Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 5Health News:The Social Leader: new Bibliomotion book redefines leadership for the Social Age 6
... coverage and other problems persist, analysis shows, , WEDNESDAY, July ... access to prescription drug coverage has ballooned since Medicare,s Part ... new analysis finds, yet seniors, ability to pay for needed ... rising drug plan costs. , "Based on nearly four years ...
... in the regulation of cell death has been identified ... led them to recommend caution when drugs called IAP ... liver conditions. , A team led by Professor Andreas ... has found that XIAP (X-chromosome-linked inhibitor of apoptosis protein) ...
... , Presidential Health Advisor , s Writings Support ... DALLAS, July 22 On the cusp of President Obama,s news conference tonight, ... care reform plan may result in denying care to a significant number of ... Administration does not consider doctors the best judges of the type of health ...
... WEDNESDAY, July 22 (HealthDay News) -- One part of the ... when deadly plaque builds up, but two other sections don,t, ... Wake Forest University Baptist Medical Center have found. , ... and left carotid arteries expands by 11 percent, on average, ...
... , , LANTANA, Fla., July ... (IHPA), announced today the launching of the , ... Get the Number , campaign is an ... for when buying storm and hurricane protection," Johnston said. "Consumers ...
... , , OAK BROOK, ... gastroenterologists, gastroenterology nurses and gastroenterology fellows, announces enhanced site content ... , , NAAP describes the ... of a physician, or by a physician or nurse other ...
Cached Medicine News:Health News:Medicare Drug Plan Still Needs Work 2Health News:Medicare Drug Plan Still Needs Work 3Health News:Critical link in cell death pathway revealed 2Health News:NCPA: White House Has Ideas on How to Ration Health Care 2Health News:Carotid Artery Sections React Differently to Plaque 2Health News:IHPA Launches Consumer Awareness Campaign for Hurricane Protection 2Health News:IHPA Launches Consumer Awareness Campaign for Hurricane Protection 3Health News:SedationFacts.org Presents Content on Policies and Conditions Regarding Alternative Methods for the Administration of Propofol 2Health News:SedationFacts.org Presents Content on Policies and Conditions Regarding Alternative Methods for the Administration of Propofol 3Health News:SedationFacts.org Presents Content on Policies and Conditions Regarding Alternative Methods for the Administration of Propofol 4
(Date:9/30/2014)... Sept. 30, 2014  Allakos Inc. announced today ... investment from current investors to fund development of ... completed following achievement of a key, pre-specified milestone ... represents an extension of the company,s Series A ... With this additional financing, Allakos has raised a ...
(Date:9/29/2014)... and DUBLIN , Sept. 29, 2014 ... "Company"), a biotechnology company pioneering the manufacturing both US ... therapies for cancer, HIV/AIDS, opportunistic infections and autoimmune diseases ... from CEO Noreen Griffin The letter follows: ... or "TNIB") received a number of calls from shareholders ...
(Date:9/29/2014)... EU5 Capsule Endoscopy Systems Market Outlook to ... report, "EU5 Capsule Endoscopy Systems Market Outlook to 2020", ... Systems market. The report provides value, in millions of ... US dollars) within market segments - Capsule Endoscopes, Capsule ... The report also provides company shares and distribution shares ...
Breaking Medicine Technology:Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 2Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 3Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 4TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 2TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 3TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 4TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 5TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 6TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 7TNI BioTech, Inc. Corporation's CEO Issues Letter to Shareholders Discussing Cytocom Dividend 8EU5 Capsule Endoscopy Systems Market Outlook to 2020 2EU5 Capsule Endoscopy Systems Market Outlook to 2020 3
... VIEJO, Calif., May 14, 2012  Bausch + Lomb, ... Barr Global President of the company,s Surgical business.  ... full suite of ophthalmic surgical products, intraocular lenses ... names as enVista™ Crystalens®, Stellaris® ...
... N.Y., May 14, 2012   Pharmaceutical manufacturers and ... requiring reporting on drug product samples distribution using XML, ... To help the pharmaceutical industry cope with the ... for ongoing Standard SPL filings, Data Conversion Laboratory (DCL) ...
Cached Medicine Technology:Bausch + Lomb Names John Barr Global President Surgical 2Bausch + Lomb Names John Barr Global President Surgical 3Coping With New FDA Mandates For Drug Sample Distribution 2